Ulcerative Colitis Uc Pipeline Insight
DelveInsight’s, “Ulcerative Colitis (UC)– Pipeline Insight, 2021,” report provides comprehensive insights about 110+ companies and 110+ pipeline drugs in Ulcerative Colitis (UC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Ulcerative Colitis (UC) Understanding
Ulcerative Colitis (UC): Overview
Ulcerative Colitis (UC) is a chronic disease of the large intestine, in which the lining of the colon become inflamed and develops tiny open sores or ulcers. Those ulcers produce pus and mucous, which causes abdominal pain. It usually begins in the rectum and spreads upwards. The inflammation causes bowel to move its content rapidly and empty frequently. Ulcerative Colitis (UC) begins gradually and become worse over the period of time. Ulcerative Colitis (UC) also known as inflammatory bowel disease. Ulcerative Colitis (UC) symptoms range from mild to severe and varies among affected people. The predominant symptoms in Ulcerative Colitis (UC) is diarrhea, which can be associated with the discharge of blood in the stool.
"Ulcerative Colitis (UC)- Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ulcerative Colitis (UC) pipeline landscape is provided which includes the disease overview and Ulcerative Colitis (UC) treatment guidelines. The assessment part of the report embraces, in depth Ulcerative Colitis (UC) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ulcerative Colitis (UC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Ulcerative Colitis (UC) R&D. The therapies under development are focused on novel approaches to treat/improve Ulcerative Colitis (UC).
Ulcerative Colitis (UC) Emerging Drugs Chapters
This segment of the Ulcerative Colitis (UC) report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ulcerative Colitis (UC) Emerging Drugs
Filgotinib: Gilead Sciences
Filgotinib is an orally available inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities. Filgotinib specifically targets, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT-dependent signaling. JAK1 plays a key role in the signaling and activity of many cytokines and growth factors and is often dysregulated in a variety of autoimmune and inflammatory diseases, as well as some malignancies.
Filgotinib was discovered and developed by Galapagos using its target and drug discovery technology platform. Filgotinib is approved and marketed as Jyseleca (200 mg and 100 mg tablets) in Europe and Japan for the treatment of adults with moderately to severely active RA. It is currently in Preregistration Phase.
Upadacitinib (ABT-494) is an oral, once daily, selective and reversible JAK inhibitor studied in several immune-mediated inflammatory diseases. It possess greater inhibitory potency for JAK1 versus JAK2, JAK3 and TYK2. JAK1 inhibition blocks the signaling of many important pro-inflammatory cytokines like interleukin IL-2, IL-6, IL-7, and IL-15, which are known to contribute for inflammatory disorders.
In 2019, RINVOQ (Upadacitinib) received USFDA and European Commission approval for adult patients with moderately to severely active rheumatoid arthritis who are intolerant to one or more disease-modifying anti-rheumatic drugs. Upadacitinib is currently under Phase 3 clinical studies for the treatment of atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, Ulcerative Colitis (UC), giant cell arteritis and Takayasu arteritis are ongoing.
Further product details are provided in the report……..
Ulcerative Colitis (UC): Therapeutic Assessment
This segment of the report provides insights about the different Ulcerative Colitis (UC) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Ulcerative Colitis (UC)
There are approx. 110+ key companies which are developing the therapies for Ulcerative Colitis (UC). The companies which have their Ulcerative Colitis (UC) drug candidates in the most advanced stage, i.e. Preregistration include, Gilead Sciences.
DelveInsight’s report covers around 110+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Ulcerative Colitis (UC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Ulcerative Colitis (UC): Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Ulcerative Colitis (UC) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ulcerative Colitis (UC) drugs.
Ulcerative Colitis (UC) Report Insights
- Ulcerative Colitis (UC) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Ulcerative Colitis (UC) Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ulcerative Colitis (UC) drugs?
- How many Ulcerative Colitis (UC) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ulcerative Colitis (UC)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ulcerative Colitis (UC) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ulcerative Colitis (UC) and their status?
- What are the key designations that have been granted to the emerging drugs?